Management of Iron Overload in Patients with Liver Cirrhosis

1. Initial Evaluation and Diagnosis

Iron overload is present in 32–44 % of patients with liver cirrhosis and usually reflects acquired hemosiderosis rather than hereditary hemochromatosis, even when the hepatic iron index exceeds 1.9. – European Association for the Study of the Liver (EASL) 1
Magnetic resonance imaging (MRI) is the preferred non‑invasive method to quantify hepatic iron concentration and should be used as the primary diagnostic tool. – EASL 1
MRI is indicated when hyperferritinemia is unexplained, biochemical iron overload is present, or liver iron staining is positive, to assess hepatic and extra‑hepatic iron stores. – EASL 1
Serum ferritin and transferrin‑saturation are recommended as initial screening tests, but results must be interpreted cautiously because ferritin can be elevated by inflammation in cirrhosis. – EASL 1
Liver biopsy is not routinely required for diagnosing hepatic iron overload; it is reserved for cases with ferritin > 1,000 µg/L or unexplained elevation of liver enzymes to evaluate fibrosis stage. – EASL 1

All cirrhotic patients should undergo non‑invasive fibrosis assessment at diagnosis using transient elastography or the FIB‑4 score. – EASL 1
A liver stiffness measurement < 6.4 kPa on transient elastography effectively rules out advanced fibrosis in hemochromatosis. – EASL 1
In individuals with ferritin < 1,000 µg/L, normal transaminases, and no hepatomegaly, the likelihood of advanced fibrosis is very low. – EASL 1

Cardiac evaluation (ECG and echocardiography) is advised for patients with severe iron overload. – EASL 1
Cardiac MRI should be performed in severe hemochromatosis with cardiac symptoms to quantify myocardial iron deposition. – EASL 1
Endocrine assessment—including screening for diabetes, hypogonadism, and thyroid dysfunction—is recommended. – EASL 1
Evaluation for arthropathy, particularly of the metacarpophalangeal joints, should be part of the work‑up. – EASL 1

Therapeutic phlebotomy is the first‑line treatment for iron overload in cirrhosis when the patient can tolerate blood removal. – American Association for the Study of Liver Diseases (AASLD) [2][3]4
Initial depletion phase: weekly removal of 500 mL of blood (≈250 mg iron) as tolerated. – AASLD [2][3]4
Hemoglobin/hematocrit must be checked before each phlebotomy; the decline should not exceed 20 % from baseline. – AASLD [2][3]4
Ferritin levels should be re‑measured after every 10–12 phlebotomy sessions to monitor progress. – AASLD [2][3]4
The therapeutic target is a serum ferritin of 50–100 µg/L. – AASLD [2][3][4][5]
After depletion, maintenance phlebotomy at individualized intervals is required to keep ferritin within the 50–100 µg/L range. – AASLD [2][3][4][5]
Iron removal does not reverse established advanced cirrhosis, but it may slow disease progression. – AASLD [2][3]6
Patients with decompensated cirrhosis who cannot undergo phlebotomy should be evaluated for liver transplantation. – AASLD [2][3]6

Iron chelation (deferoxamine 20–40 mg/kg/day or oral deferasirox) is indicated for patients intolerant of phlebotomy, especially those with anemia or dyserythropoiesis. – AASLD [2][3][4][5]7
Chelation removes only 10–20 mg of iron per day, which is substantially less efficient than phlebotomy’s ~250 mg per week. – AASLD [2][7]

Vitamin C supplements should be avoided because they increase iron mobilization and oxidative stress. – AASLD [2][3][4][5]6
Iron‑containing supplements must be discontinued. – AASLD [2][3]4
Raw shellfish should be avoided due to the heightened risk of Vibrio vulnificus infection in iron‑overloaded individuals. – AASLD [2][3]6
Restricting dietary iron intake provides minimal benefit (≈2–4 mg/day reduction) and is not required. – AASLD [2][3]6

All cirrhotic patients, irrespective of iron‑depletion status, should undergo abdominal ultrasound every 6 months for HCC screening. – EASL 1
Surveillance must continue indefinitely after successful iron removal because cirrhosis itself maintains cancer risk. – EASL 1
Patients with advanced fibrosis (F3) should also be screened for HCC even if cirrhosis is not yet present. – EASL 1
When ultrasound quality is suboptimal, contrast‑enhanced CT or MRI should be employed. – EASL 1

Iron re‑accumulation is common; ongoing monitoring of ferritin (and, when needed, MRI) is essential, with maintenance phlebotomy adjusted accordingly. – AASLD [2][3]5

Adequate iron depletion before liver transplantation is critical; insufficient removal has been linked to higher peri‑operative mortality from cardiac and infectious complications. – AASLD [2][3][6][7]
When iron is adequately depleted pre‑transplant, post‑transplant survival is comparable to that of other etiologies. – AASLD [2][3]6